Pre-market: PSG.DE (PharmaSGP SE XETRA) €29.00 oversold bounce: key level €28.52
The PSG.DE stock opened pre-market at €29.00 on XETRA on 15 Jan 2026 and shows an early oversold bounce setup versus short-term averages. We see volume running at 12,424 shares, or 2.30x average, a sign of heightened interest. Price sits just above the 50‑day at €28.52 and below the year high of €30.00, which frames an actionable short-term trade for traders watching an oversold bounce strategy. Below we break down market signals, valuation, risk, and price targets for PharmaSGP Holding SE on XETRA in Germany.
PSG.DE stock quick facts and market snapshot
PharmaSGP Holding SE (PSG.DE) trades on XETRA in Germany at €29.00 with a market cap of €333.86M and 11,512,500 shares outstanding. The stock shows EPS €1.68 and PE 17.26, with a daily range today between €28.60 low and €29.00 high. Volume is 12,424, above the 50‑day average volume 5,399, giving a relative volume of 2.30.
We note the 50‑day average price is €28.52 and the 200‑day average is €26.10, which sets nearby technical support levels for an oversold bounce trade.
Why this looks like an oversold bounce setup
Short-term flows support a bounce case: price tested the €28.52 50‑day area and buyers stepped in at higher than normal volume. That concentration of activity and quick rebound into the pre-market suggests a short-term reversal opportunity for momentum traders.
Sector context helps. Healthcare in Germany has posted modest gains recently and sector average PE sits near 31.63, while PSG.DE’s PE 17.26 is lower, which can attract value- and earnings-focused buyers during short-term dips.
Fundamentals and valuation that back the bounce thesis
PharmaSGP reports solid trailing metrics: revenue per share €10.58, net income per share €1.71, free cash flow per share €1.79, and cash per share €2.54. The company shows low leverage with debt to equity 0.02 and a strong current ratio 2.68, which reduces balance-sheet risk for short-term holders.
Valuation multiples are mixed. Price to sales is 2.73 and price to book is 9.12. Margins remain healthy with gross margin 90.55% and operating margin 23.06%, supporting an earnings‑backed bounce rather than a pure speculative move.
Technical levels, trade plan and Meyka AI grade
Key technicals to watch: support near the 50‑day €28.52 and stronger support at the 200‑day €26.10. Immediate resistance sits at the year high €30.00 and psychological €32.00. For a tactical oversold bounce trade we propose an entry near €29.00, a tight initial stop below €28.20, and a first target at €31.00 with a secondary target at €33.00.
Meyka AI rates PSG.DE with a score out of 100: 75.83 / B+ (BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Use the grade as context, not investment advice.
Meyka AI forecast and price projections
Meyka AI’s forecast model projects €27.36 for the next 12 months, €29.48 for 3 years and €31.56 for 5 years. Versus the current €29.00, the model implies a near-term downside of -5.64%, a 3‑year upside of +1.65%, and a 5‑year upside of +8.84%. Forecasts are model‑based projections and not guarantees.
Combine these model outputs with the short-term technical bounce plan above: the forecast flags limited near-term upside by the model, while the trade plan targets a tactical rebound to the €31–€33 range.
Risks, catalysts and what to watch next
Risks include low inventory turnover (days of inventory 309.67), which can pressure working capital, and a high payout ratio 0.83 relative to earnings growth that could limit reinvestment. Regulatory shifts in OTC drug approvals and distribution changes in EU markets are potential catalysts.
Watch upcoming news items, quarterly results and volume spikes. Follow company updates on its website and official XETRA announcements for event-driven moves: PharmaSGP website and the exchange profile on Börse Frankfurt for official filings.
Final Thoughts
PSG.DE stock looks suited for a short-term oversold bounce trade in the pre-market session on 15 Jan 2026. Price at €29.00 sits just above the 50‑day €28.52, with elevated volume (12,424, rel vol 2.30) supporting a quick rebound scenario. Fundamentals show solid margins, low leverage, and EPS €1.68 which reduce downside risk for tactical trades. Meyka AI’s model projects €27.36 over 12 months (implied -5.64%) but a modest multi-year upside to €31.56 in five years (+8.84%). For traders we recommend a disciplined entry near €29.00, stop below €28.20, first target €31.00, and reassess on higher volume or new fundamental news. Remember, forecasts are model‑based projections and not guarantees. Use position sizing and risk limits when trading an oversold bounce setup.
FAQs
Is PSG.DE stock a buy for a short-term bounce?
PSG.DE stock shows a short-term bounce setup pre-market at €29.00, with rel vol 2.30 and support at €28.52. Traders can consider a tactical long with a tight stop, but manage risk and monitor volume and company news.
What are realistic price targets for PSG.DE stock?
For a tactical oversold bounce we set a near target at €31.00 and a secondary at €33.00. Meyka AI’s 3‑year model target is €29.48 and 5‑year €31.56. These figures are model projections and not guarantees.
How does PSG.DE stock compare to the healthcare sector?
PSG.DE stock trades at PE 17.26, below the sector average near 31.63, and shows strong margins and low debt. That relative valuation can attract buyers when short-term technicals trigger a bounce.
Where can I find official PSG.DE filings and company news?
Check PharmaSGP’s investor pages at PharmaSGP website and the official exchange profile at Börse Frankfurt for filings and announcements.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
